BRIEF published on 11/29/2024 at 07:36, 1 year 3 months ago Evotec annonce le départ de son directeur opérationnel et une restructuration interne Changement De Direction Evotec Médicaments Départ Du COO Restructuration Interne
BRIEF published on 11/29/2024 at 07:36, 1 year 3 months ago Evotec Announces COO Departure and Internal Restructuring Pharmaceuticals Management Change Evotec COO Departure Internal Restructuring
PRESS RELEASE published on 11/29/2024 at 07:31, 1 year 3 months ago Evotec announces change in Management Board Evotec SE announces the departure of Chief Operating Officer Dr Craig Johnstone effective December 31, 2024, with internal distribution of responsibilities. Management praises Johnstone's contribution and commitment Global Operations Chief Operating Officer Evotec SE Management Board Dr Craig Johnstone
BRIEF published on 11/22/2024 at 17:00, 1 year 4 months ago Evotec SE Comments on Withdrawal of Halozyme's Offer Shareholder Value Evotec SE Acquisition Proposal Halozyme Therapeutics Non-binding Offer
BRIEF published on 11/22/2024 at 17:00, 1 year 4 months ago Evotec SE commente le retrait de l'offre d'Halozyme Evotec SE Valeur Actionnariale Proposition D'acquisition Thérapeutique Halozyme Offre Sans Engagement
PRESS RELEASE published on 11/22/2024 at 16:55, 1 year 4 months ago EQS-Adhoc: Comment on withdrawn non-binding offer Evotec SE acknowledges withdrawal of non-binding offer by Halozyme Therapeutics Inc. for acquisition. Management reiterates confidence in standalone strategy Acquisition Evotec SE Halozyme Therapeutics Inc. Withdrawn Offer Standalone Strategy
BRIEF published on 11/14/2024 at 22:56, 1 year 4 months ago Evotec SE répond à l'intérêt d'Halozyme Evotec SE Reprendre Thérapeutique Halozyme Manifestation D'intérêt 11 EUR Par Action
BRIEF published on 11/14/2024 at 22:56, 1 year 4 months ago Evotec SE Responds to Interest from Halozyme Evotec SE Takeover Halozyme Therapeutics Expression Of Interest EUR 11 Per Share
PRESS RELEASE published on 11/14/2024 at 22:51, 1 year 4 months ago EQS-Adhoc: Comment on media report Evotec SE receives non-binding expression of interest from Halozyme Therapeutics Inc. for a takeover offer of EUR 11.00 per share Evotec SE Takeover Offer Expression Of Interest Halozyme Therapeutics Inc. EUR 11.00 Per Share
BRIEF published on 11/06/2024 at 07:05, 1 year 4 months ago Evotec SE Reports Strategic Progress and Revenue Growth Amid Challenges Strategic Partnerships 2024 Forecasts Biologics Growth Evotec Financial Results Priority Reset Initiative
Published on 03/23/2026 at 02:00, 5 hours 40 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 13:30, 2 days 18 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/23/2026 at 07:30, 10 minutes ago Nordex Group receives new order from Serbia for 70 MW
Published on 03/23/2026 at 07:30, 10 minutes ago Just – Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
Published on 03/23/2026 at 07:30, 10 minutes ago Salzgitter Group delivers pretax result close to breakeven
Published on 03/23/2026 at 07:30, 10 minutes ago q.beyond intends to grow revenues to € 250 million by 2028 – “2028 Strategy” leverages sector focus, AI, and internationalisation
Published on 03/23/2026 at 07:00, 40 minutes ago Sonova presents renewed strategy to expand market leadership with ambition to reach CHF 6 billion in revenue by FY 2030/31
Published on 03/20/2026 at 19:00, 2 days 12 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 12 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 13 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 13 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
